| Ankylosing spondylitis

Bimzelx vs Celebrex

Side-by-side clinical, coverage, and cost comparison for ankylosing spondylitis.
Deep comparison between: Bimzelx vs Celebrex with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsCelebrex has a higher rate of injection site reactions vs Bimzelx based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Celebrex but not Bimzelx, including UnitedHealthcare
Sign up to reveal the full AI analysis
Bimzelx
Celebrex
At A Glance
SC injection
Every 4-8 weeks
IL-17A and F antagonist
Oral
Once or twice daily
COX-2 inhibitor
Indications
  • Psoriasis vulgaris
  • Arthritis, Psoriatic
  • Non-Radiographic Axial Spondyloarthritis
  • Ankylosing spondylitis
  • Hidradenitis Suppurativa
  • Degenerative polyarthritis
  • Rheumatoid Arthritis
  • Juvenile rheumatoid arthritis
  • Ankylosing spondylitis
  • Primary dysmenorrhea
Dosing
Psoriasis vulgaris 320 mg SC at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter; for patients weighing 120 kg or more, consider 320 mg every 4 weeks after Week 16.
Arthritis, Psoriatic, Non-Radiographic Axial Spondyloarthritis, Ankylosing spondylitis 160 mg SC every 4 weeks; for Arthritis, Psoriatic with coexistent moderate to severe plaque psoriasis, use the plaque psoriasis dosing regimen.
Hidradenitis Suppurativa 320 mg SC at Weeks 0, 2, 4, 6, 8, 10, 12, 14, and 16, then every 4 weeks thereafter.
Degenerative polyarthritis 200 mg once daily or 100 mg twice daily, oral.
Rheumatoid Arthritis 100 mg to 200 mg twice daily, oral.
Juvenile rheumatoid arthritis 50 mg twice daily for patients 10-25 kg; 100 mg twice daily for patients >25 kg, oral.
Ankylosing spondylitis 200 mg once daily or 100 mg twice daily, oral; if no effect after 6 weeks, may trial 400 mg daily.
Primary dysmenorrhea 400 mg initially, followed by 200 mg if needed on day 1; 200 mg twice daily on subsequent days, oral.
Contraindications
—
  • Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib or any components of the drug product
  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
  • Setting of CABG surgery
  • Demonstrated allergic-type reactions to sulfonamides
Adverse Reactions
Most common (>=1%) Upper respiratory infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, herpes simplex infections, acne, folliculitis, fatigue, diarrhea, urinary tract infection
Serious Suicidal ideation and behavior, serious infections, liver biochemical abnormalities, inflammatory bowel disease
Postmarketing Conjunctivitis, esophageal candidiasis
Most common (>=2%) Headache, dyspepsia, upper respiratory infection, diarrhea, sinusitis, abdominal pain, nausea, back pain, peripheral edema, rhinitis, pharyngitis, rash, flatulence, dizziness, insomnia.
Serious Cardiovascular thrombotic events, GI bleeding/ulceration/perforation, hepatotoxicity, hypertension, heart failure and edema, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, hematologic toxicity.
Postmarketing Vasculitis, deep venous thrombosis, angioedema, liver necrosis, hepatic failure, agranulocytosis, aplastic anemia, pancytopenia, aseptic meningitis, fatal intracranial hemorrhage, interstitial nephritis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, DRESS, AGEP, fixed drug eruption.
Pharmacology
Bimekizumab-bkzx is a humanized IgG1 monoclonal antibody that selectively binds IL-17A, IL-17F, and IL-17AF cytokines, inhibiting their interaction with the IL-17 receptor complex and suppressing the release of proinflammatory cytokines and chemokines.
Celecoxib is a selective COX-2 inhibitor that reduces prostaglandin synthesis in peripheral tissues and the CNS, producing analgesic, anti-inflammatory, and antipyretic effects; at therapeutic doses it does not inhibit platelet aggregation or prolong bleeding time.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bimzelx
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
View full coverage details ›
Celebrex
  • Covered on 5 commercial plans
  • PA (0/12) · Step Therapy (4/12) · Qty limit (11/12)
View full coverage details ›
UnitedHealthcare
Bimzelx
  • Covered on 4 commercial plans
  • PA (5/8) · Step Therapy (5/8) · Qty limit (5/8)
View full coverage details ›
Celebrex
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
View full coverage details ›
Humana
Bimzelx
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
View full coverage details ›
Celebrex
  • Covered on 0 commercial plans
  • PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
$15/fillfill
Bimzelx Bridge
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Celebrex.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
BimzelxView full Bimzelx profile
CelebrexView full Celebrex profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.